Structural basis for agonism and antagonism of hepatocyte growth factor.

Proceedings of the National Academy of Sciences of the United States of America
W David TolbertH Eric Xu

Abstract

Hepatocyte growth factor (HGF) is an activating ligand of the Met receptor tyrosine kinase, whose activity is essential for normal tissue development and organ regeneration but abnormal activation of Met has been implicated in growth, invasion, and metastasis of many types of solid tumors. HGF has two natural splice variants, NK1 and NK2, which contain the N-terminal domain (N) and the first kringle (K1) or the first two kringle domains of HGF. NK1, which is a Met agonist, forms a head-to-tail dimer complex in crystal structures and mutations in the NK1 dimer interface convert NK1 to a Met antagonist. In contrast, NK2 is a Met antagonist, capable of inhibiting HGF's activity in cell proliferation without clear mechanism. Here we report the crystal structure of NK2, which forms a "closed" monomeric conformation through interdomain interactions between the N- domain and the second kringle domain (K2). Mutations that were designed to open up the NK2 closed conformation by disrupting the N/K2 interface convert NK2 from a Met antagonist to an agonist. Remarkably, this mutated NK2 agonist can be converted back to an antagonist by a mutation that disrupts the NK1/NK1 dimer interface. These results reveal the molecular determinants tha...Continue Reading

References

Dec 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·G HartmannW Birchmeier
Mar 1, 1991·Acta Crystallographica. Section A, Foundations of Crystallography·T A JonesM Kjeldgaard
Apr 1, 1997·Journal of Molecular Graphics & Modelling·R M Esnouf
Mar 25, 1999·Acta Crystallographica. Section D, Biological Crystallography·R M Esnouf
Oct 7, 2003·Proceedings of the National Academy of Sciences of the United States of America·Ermanno GherardiP Jonathan G Butler
Dec 20, 2003·Nature Reviews. Molecular Cell Biology·Carmen BirchmeierGeorge F Vande Woude
May 29, 2004·The EMBO Journal·Jennifer StamosChristian Wiesmann
Jun 26, 2004·The Journal of Biological Chemistry·Daniel KirchhoferRobert A Lazarus
Jul 21, 2004·Cancer Cell·Monica Kong-BeltranDineli Wickramasinghe
Mar 23, 2005·Oncogene·Qian XieGeorge F Vande Woude
Jun 14, 2005·Biochemical and Biophysical Research Communications·Kunio Matsumoto, Toshikazu Nakamura
Jul 19, 2005·Proceedings of the National Academy of Sciences of the United States of America·Chong-Feng GaoGeorge F Vande Woude
Mar 16, 2006·Proceedings of the National Academy of Sciences of the United States of America·Ermanno GherardiDmitri I Svergun
Mar 21, 2007·Proceedings of the National Academy of Sciences of the United States of America·Daniel KirchhoferRobert A Lazarus
Sep 7, 2007·Proceedings of the National Academy of Sciences of the United States of America·W David TolbertH Eric Xu
Feb 23, 2008·Journal of Molecular Biology·Mark YoulesErmanno Gherardi
Jan 1, 1997·Methods in Enzymology·E A Merritt, D J Bacon
Mar 26, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Joseph Paul EderPatricia M LoRusso
Apr 25, 2009·The American Journal of Pathology·Nils BuchsteinSabine A Eming

❮ Previous
Next ❯

Citations

Mar 26, 2013·Bioorganic & Medicinal Chemistry·Laurent RaibautOleg Melnyk
Jan 25, 2012·Nature Reviews. Cancer·Ermanno GherardiGeorge Vande Woude
Jul 27, 2011·Proceedings of the National Academy of Sciences of the United States of America·Douglas S JonesJennifer R Cochran
Oct 13, 2010·The Journal of Biological Chemistry·Kyle E LandgrafRobert A Lazarus
Apr 23, 2013·International Journal of Hepatology·Neeta K Venepalli, Laura Goff
May 27, 2014·Nature Chemical Biology·Kyle E LandgrafRobert A Lazarus
Dec 3, 2014·FEBS Letters·Cassie J LiuJennifer R Cochran
Jun 3, 2011·Growth Factors·Barbara Grzelakowska-Sztabert, Magdalena Dudkowska
Sep 28, 2010·Expert Opinion on Investigational Drugs·Giulia M StellaPaolo M Comoglio
Jan 19, 2011·European Journal of Cell Biology·Hartmut H Niemann
Nov 16, 2012·The Journal of Investigative Dermatology·Chonglin LuoStefan B Eichmüller
Aug 3, 2014·Expert Opinion on Therapeutic Targets·Patricia B GauleMichael J Duffy
May 26, 2015·Laboratory Investigation; a Journal of Technical Methods and Pathology·Kate Lynn J BillRaphael E Pollock
Oct 22, 2013·Progress in Biophysics and Molecular Biology·Rajesh N Gacche, Rohan J Meshram
Nov 26, 2015·Angewandte Chemie·Ryosuke UekiShinsuke Sando
Aug 30, 2018·Chemistry : a European Journal·Shan ChenHuang-Hao Yang
May 14, 2016·Oncotarget·Elisabetta GrilloStefania Mitola
Nov 16, 2018·The Journal of Experimental Medicine·Uzodinma U UcheLawrence P Kane
Nov 5, 2014·Biomedicines·Ognoon MungunsukhRegina M Day
Aug 14, 2019·European Journal of Medicinal Chemistry·A GolonkoW Lewandowski
Apr 17, 2021·Biochemical Society Transactions·Edmond M LinossiNatalia Jura
Jun 19, 2021·Angewandte Chemie·Momoko AkiyamaShinsuke Sando
Aug 15, 2014·ACS Synthetic Biology·Luis DiambraMark Isalan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

© 2021 Meta ULC. All rights reserved